Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Interest Expenses (2021 - 2025)

Historic Interest Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $43292.0.

  • SAB Biotherapeutics' Interest Expenses fell 4452.3% to $43292.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $248078.0, marking a year-over-year decrease of 2376.33%. This contributed to the annual value of $318401.0 for FY2024, which is 98.86% up from last year.
  • SAB Biotherapeutics' Interest Expenses amounted to $43292.0 in Q3 2025, which was down 4452.3% from $64345.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Interest Expenses peaked at $93119.0 during Q2 2024, and registered a low of $43292.0 during Q3 2025.
  • Moreover, its 5-year median value for Interest Expenses was $74434.0 (2021), whereas its average is $74049.0.
  • As far as peak fluctuations go, SAB Biotherapeutics' Interest Expenses skyrocketed by 3232.59% in 2022, and later tumbled by 4452.3% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Interest Expenses stood at $66275.0 in 2021, then surged by 32.33% to $87699.0 in 2022, then fell by 11.2% to $77879.0 in 2023, then dropped by 8.99% to $70876.0 in 2024, then tumbled by 38.92% to $43292.0 in 2025.
  • Its last three reported values are $43292.0 in Q3 2025, $64345.0 for Q2 2025, and $69565.0 during Q1 2025.